LAUREN GRAU is counsel in Sidley’s Technology and IP Transactions practice in Dallas. Lauren advises emerging and public companies, private equity firms and individuals on a wide range of intellectual property-related issues in connection with mergers, acquisitions, divestitures, joint ventures, collaborations, strategic investments, financing transactions, licensing and services agreements. Her practice focuses on representing clients in the life sciences, telecommunications, information technology, software, media and consumer products sectors. In addition, Lauren has experience in trademark branding, prosecution, and protection; and copyright protection and enforcement.
She also has experience in a variety of phases of patent litigation and has represented clients in various United States District Courts and in the International Trade Commission in a wide range of technologies, including telecommunications, smartphone technologies, semiconductor fabrication and packaging, consumer electronics and cosmetic chemistry.
Transactional Experience: Life Sciences
- Represented Yuhan Corporation in its licensing and collaboration agreement with Gilead Sciences, Inc. to co-develop novel therapeutic candidates for the treatment of patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
- Represented Yuhan Corporation in its licensing agreement with Janssen, a division of Johnson & Johnson, for the development, manufacturing and commercialization of lazertinib, a non-small cell lung cancer drug candidate.
- Represented Nektar Therapeutics in its in multi-billion dollar global strategic development and commercialization collaboration with Bristol-Myers Squibb Company (NYSE:BMY) for Nektar’s CD122-biased agonist, NKTR-214. Under the terms of the agreement, the companies will jointly develop and commercialize NKTR-214 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo plus Yervoy (ipilimumab) in more than 20 indications across nine tumor types–including melanoma, renal cell carcinoma, non-small cell lung cancer, bladder and triple negative breast cancer–as well as potential combinations with other anti-cancer agents from either of the respective companies and/or third parties.
- Represented Medivation, Inc., a biopharmaceutical company, in its acquisition of all worldwide rights to talazoparib (formerly referred to as BMN 673) from BioMarin Pharmaceutical, Inc.
- Represented GlaxoSmithKline on a novel public-private joint venture and collaboration with the University of North Carolina at Chapel Hill dedicated to seeking a cure for HIV. GSK will invest $4 million into the partnership each year during the five-year research agreement.
- Represented Genentech, a member of the Roche Group, in its agreement to acquire Seragon Pharmaceuticals, Inc., a biotechnology company focused on selective estrogen receptor degraders to treat hormone receptor-positive breast cancer, for a total amount of up to $1.7 billion.
- Represented Roche Molecular Systems in its acquisition of Genia Technologies, Inc., a DNA sequencing company, for up to $350 million, and its acquisition of Bina Technologies Inc., the creator of a big data platform for managing and processing next generation sequencing (NGS) data.
Transactional Experience: Telecommunications, Information Technology, Media, Consumer Products
- Represented TSG Consumer Partners and its portfolio companies in numerous matters, including the $1.2 billion sale of portfolio company, IT Cosmetics, LLC, to L’Oreal.
- Represented Siris Capital Group, LLC in its $654 million acquisition of Xura, Inc. (formerly Comverse).
- Represented eBay in numerous matters, including its acquisition of Ticketbis.
- Represented Aon in numerous matters, including its acquisition of Modern Survey and StoneRiver National Flood Services.
- Represented Churchill Downs in its acquisition of Big Fish Games, one of the world’s largest producers and distributors of mobile and online games, for up to $885 million.
- Represented MasterCard in agreements for the development, distribution and hosting of multi-function platforms for customer and cardholder loyalty, travel and small business focused suite of products and services.
- Represented KPMG, OMERS Private Equity, Dell, R.R. Donnelley & Sons Company, FLIR Systems, Inc., Thompson Street Capital Partners and a number of private equity funds in M&A and financing transactions.
Before attending law school, Lauren worked for five years for a leading competitive local exchange carrier as a telecommunications engineer. While attending law school, Lauren interned with the Honorable Harlin D. Hale at the United States Bankruptcy Court for the Northern District of Texas and served as Head Casenotes & Comments Editor of the Houston Journal of International Law for 2007-08.
Lauren has represented clients on various immigration and asylum issues before the Dallas Immigration Court. She is also involved in Sidley’s Emerging Enterprises Pro Bono Program, which provides free legal support to eligible small and medium-sized for-profit enterprises and market-focused NGOs and non-profits that have a clear social impact in developing countries across Africa, Asia, Central and South America and the Caribbean.
In 2010, Lauren received the “Outstanding Young Associate Award” for her pro bono work with the Human Rights Initiative of North Texas.
Admissions & Certifications
- U.S. District Court, E.D. of Texas
- U.S. District Court, N.D. of Texas
- University of Houston Law Center, J.D., 2008
- University of Texas at Austin, B.S. in Biochemistry, 2000